| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| Gene symbol | IL15 | Synonyms | IL-15 | Type of gene | protein-coding |
| Chromosome | 4 | Map location | 4q31.21 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | interleukin 15 | ||||
| GTO ID | GTC0825 |
| Trial ID | ChiCTR1900026083 |
| Disease | B-Cell Malignancy |
| Altered gene | CD19|CD20|IL15 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | ICG132|ICG134 |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | CD19/CD20/CARVAC-targeted Chimeric antigen receptor gene-modified T cells therapy in Patients with relapsed/refractory B cell malignancies |
| Year | 2019 |
| Country | China |
| Company sponsor | The First Affiliated Hospital of Xiamen University |
| Vector information | |||||
|
|||||
| Cohort1: ICG132 | |||||||||
|
|||||||||
| Cohort2: ICG134 | |||||||||
|
|||||||||